TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06604624
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Study: NCT04284787
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06425055
Drug: Vonafexor
Normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24
Study: NCT06177457
Drug: PF-07293893
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days
Study: NCT06177457
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
Study: NCT05119296
Drug: Pembrolizumab (Keytruda)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
Study: NCT06287567
Drug: Lusutrombopag Oral Tablet
Normalized name: lusutrombopag Oral Tablet
DrugBank: Lusutrombopag (DB13125)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
Study: NCT06784076
Drug: Anifrolumab
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
Study: NCT06236451
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
Study: NCT06236451
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
Study: NCT06317636
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine infused intravenously over 40 minutes
Study: NCT06548412
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06548412
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06548412
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT06331845
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 on Days 1 and 8
Study: NCT06331845
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a total of 80-100 mg/m2 for d1-3
Study: NCT06331845
Drug: Paclitaxel protein-bound
Normalized name: Paclitaxel Protein-Bound
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260 mg/m2 on Day 1
Study: NCT06331845
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg on Day 1
Study: NCT06231563
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous ketamine infusion 0.5 mg/kg
Study: NCT06231563
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous remimazolam infusion 0.25 mg/kg
Study: NCT06798675
Drug: nC-001
Normalized name: 9-NC
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solid dosage form single dose
Study: NCT06799442
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mic dexmedetomidine which is diluted to 2ml.
Study: NCT06032546
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06032546
Drug: Placebo for Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06032546
Drug: ABBV-382
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06032546
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) Injection
Study: NCT06382155
Drug: Vosoritide Injection
Normalized name: vosoritide Injection
DrugBank: Vosoritide (DB11928)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental Drug Lyophilized powder for reconstitution
Study: NCT06382155
Drug: Human Growth Hormone
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial product containing somatotropin
Study: NCT05820685
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
Study: NCT05997485
Drug: Nirmatrelvir/Ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
Study: NCT06370195
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06179108
Drug: LB-102
Normalized name: LB-102
DrugBank: LB-102 (DB19214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Study: NCT06249191
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06249191
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06249191
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06016738
Drug: Palazestrant
Normalized name: Palazestrant
DrugBank: Palazestrant (DB18971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
Study: NCT06016738
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
Study: NCT06016738
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
Study: NCT06016738
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
Study: NCT06016738
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
Study: NCT05754073
Drug: 1. Intranasal oxytocin spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
Study: NCT05754073
Drug: 3. Intranasal Oxytocin spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
Study: NCT05819684
Drug: SHR-4602 for injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: be administered via intravenous (IV) infusion
Study: NCT05776797
Drug: Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal medication therapy according to the prescription of the physician.
Study: NCT05700448
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT05700448
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05700448
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05478499
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05345990
Drug: Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)
Normalized name: Hepatitis B immunoglobulin (human)
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day
Study: NCT05931484
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT04728932
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous infusion of Levosimendan over 24h
Study: NCT04728932
Drug: Placebo of Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous infusion of Placebo of Levosimendan over 24h
Study: NCT05130866
Drug: REC-2282
Normalized name: REC-994
DrugBank: REC-994 (DB15616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
Study: NCT05803434
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks.
Study: NCT04127968
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in intervention group will receive 50,000 IU vitamin A after being randomized.
Study: NCT04127968
Drug: Oil
Normalized name: Oil
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children in control group will receive equal volume of oil.
Study: NCT05235737
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
Study: NCT05235737
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
Study: NCT05910827
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
Study: NCT05910827
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Study: NCT06287151
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine is an alpha-2-agonist which is commonly used as an adjunct in spinal anesthesia and caudal anesthesia to improve both the quality and duration of blockade.
Study: NCT06287151
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5.3. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
Study: NCT06798727
Drug: High Hyal Plus
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
Study: NCT06045936
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 teaspoons of 2% lidocaine injection
Study: NCT05677763
Drug: OM-85
Normalized name: OM-85
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
Study: NCT04806451
Drug: Crinecerfont
Normalized name: Crinecerfont
DrugBank: Crinecerfont (DB18518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF type 1 receptor antagonist
Study: NCT06800404
Drug: Autologous HB-adMSCs
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous HB-adMSCs
Study: NCT05097378
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity
Study: NCT05563480
Drug: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study: NCT05563480
Drug: Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study: NCT05563480
Drug: TQB2618 injection; Penpulimab injection
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study: NCT05996523
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
Study: NCT04605549
Drug: CIN-107 2 mg dosing
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Study: NCT04605549
Drug: CIN-107 4 mg dosing
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Study: NCT04605549
Drug: CIN-107 8 mg dosing
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
Study: NCT05076175
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04908956
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home.
Study: NCT05273398
Drug: nasal diazepam
Normalized name: diazepam Nasal Spray
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal administration of diazepam
Study: NCT05906498
Drug: Acetyl cysteine
Normalized name: Acetyl cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
Study: NCT05906498
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vitamin E possessing an anti-inflammatory action
Study: NCT04822961
Drug: Senaparib
Normalized name: Senaparib
DrugBank: Senaparib (DB17163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg capsules
Study: NCT06801418
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05445778
Drug: Mirvetuximab soravtansine plus Bevacizumab
Normalized name: mirvetuximab soravtansine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
Study: NCT05445778
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Bevacizumab 15mg/kg every 3 weeks
Study: NCT05894577
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
Study: NCT06147622
Drug: Prazosin + cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.
Study: NCT06147622
Drug: KT110
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.
Study: NCT06797622
Drug: Trastuzumab deruxtecan (T-DXd)
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd)
Study: NCT06654726
Drug: aldafermin
Normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aldafermin
Study: NCT05303090
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT05303090
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT06546384
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d.
Study: NCT06801730
Drug: Irinotecan liposome combined with bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
Study: NCT06346691
Drug: Doxofylline
Normalized name: Doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.